

Eloxx Pharma brings Jasbir Sehra on Board

March 1, 2018 | News

Since 2016, Sehra has served as the President and Chief Executive Officer of Keros Therapeutics Inc., a preclinical stage biopharmaceutical company focused on rare muscle disorders.



US biopharmaceutical company Eloxx Pharmaceuticals, Inc. has recently announced the appointment of Dr. Jasbir Sehra to its Board of Directors.

Sehra is currently the President and Chief Executive Officer of Vancouver based Keros Pharmaceuticals, and was previously the Co-founder and Chief Scientific Officer at Acceleron Pharma Inc.

Since 2016, Sehra has served as the President and Chief Executive Officer of Keros Therapeutics Inc., a preclinical stage biopharmaceutical company focused on rare muscle disorders. Prior to starting Keros, Sehra was Chief Scientific Officer at Ember Therapeutics, and Co-founder and Chief Scientific Officer at Acceleron Pharma.

Sehra was an early scientist at Genetics institute, Inc. where he progressed to leadership roles. He was a member of the senior research management team at Wyeth (now Pfizer) following the merger with Genetics Institute. He earned his degrees in Biochemistry from the University of Southampton, UK and completed his postdoctoral work with Nobel Laureate, H. Gobind Khorana, at the Massachusetts Institute of Technology.